Search Within

Miguel-Angel Perales

Formats
  1. Meeting Abstract (499)
  2. Journal Article (364)
  3. Review (29)
  4. Research Letter (19)
  5. Guidelines (12)
  6. Book Section (10)
  7. Editorial (6)
  8. Correspondence (5)
  9. Book Whole (1)
  10. Miscellaneous (1)
Groups
  1. Bone Marrow Transplant (946)
  2. Center for Hematologic Malignancies (946)
  3. Department of Medicine (946)
  4. Hematologic Malignancies, Division of (946)
  5. Survivorship Research (477)
  6. CTCR Scholars (413)

More Groups

People
  1. Sergio Giralt (429)
  2. Sean Devlin (304)
  3. Ann Jakubowski (248)
  4. Esperanza Papadopoulos (238)
  5. Gunjan Shah (206)
  6. Molly Maloy (196)

More People

Years
  1. 2025 (34)
  2. 2024 (76)
  3. 2023 (101)
  4. 2022 (95)
  5. 2021 (68)
  6. 2020 (93)

More Years

Publications
  1. Blood (264)
  2. Biology of Blood and Marrow Transplantation (220)
  3. Bone Marrow Transplantation (86)
  4. Transplantation and Cellular Therapy (68)
  5. Blood Advances (46)
  6. Journal of Clinical Oncology (32)

More Publications

Publishers
  1. American Society of Hematology (312)
  2. Elsevier Inc. (303)
  3. Nature Publishing Group (113)
  4. American Society of Clinical Oncology (32)
  5. Oxford University Press (18)
  6. John Wiley & Sons (17)

More Publishers

Results (946)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TNC/Kg and CD34+/Kg cell dose impact on patient engraftment after allogeneic transplant with conventional bone marrow; Better predictability of graft content needed
    Meeting Abstract

    Davis, E.; Feuer, E.; Rapoport, C.; Lobaugh, S.; Devlin, S. M.; Archer, A.; Chinapen, S.; Federman, J.; Kelly, A.; Klein, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the ZUMA trials cohorts
    Meeting Abstract

    Raj, S.; Xie, J.; Fei, T.; Song, Q.; Kim, J. J.; To, C.; van den Brink, M. R. M.; Perales, M. A.; Mattie, M.; Shouval, R.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • 18F-FDG PET/CT imaging biomarkers for car-T cell therapy outcomes in large-B-cell lymphoma
    Meeting Abstract

    Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M.; Luttwak, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma
    Journal Article

    Dahi, P. B.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Chinapen, S. A.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Dreger, P.; Westin, J.; Oluwole, O.; Kersten, M. J.; Miklos, D.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Initial first-in-human results: CD33-deleted hematopoietic stem and progenitor cells display normal engraftment after hematopoietic cell transplant (HCT) and tolerate post-hct gemtuzumab ozogamicin (GO) without cytopenias
    Meeting Abstract

    Tomlinson, B.; Suh, H. C.; Koura, D.; Koehne, G.; Cho, C.; Bambace, N. M.; Bernard, L.; Shah, N.; Walter, R. B.; DiPersio, J. F.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Study design and rationale of stargaze - A phase 2 clinical trial evaluating apraglutide in patients with steroid-refractory gastrointestinal (GI) acute graft-versus-host disease (AGvHD)
    Meeting Abstract

    Zeiser, R.; Perales, M. A.; Adelman, H.; Bolognani, F.; Hockenbery, D.
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Geriatric assessment and outcomes of allogeneic hematopoietic cell transplantation in older patients
    Meeting Abstract

    Dahi, P. B.; Shahrokni, A.; Flynn, J.; Devlin, S. M.; Chinapen, S. A.; Ayala, J.; Brown, S.; Bugen, S.; Cho, C.; Gyurkocza, B.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save